0.2315 USD
+0 (+0.65%)
0.234 USD
+0 (+1.08%)
We assign a fundamental rating of 2 out of 10 to ADIL. ADIL was compared to 191 industry peers in the Pharmaceuticals industry. ADIL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ADIL is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
- In the past year ADIL has reported negative net income.
- In the past year ADIL has reported a negative cash flow from operations.
- ADIL had negative earnings in each of the past 5 years.
- In the past 5 years ADIL always reported negative operating cash flow.
1.2 Ratios
- ADIL has a Return On Assets of -142.26%. This is amonst the worse of the industry: ADIL underperforms 84.82% of its industry peers.
- ADIL has a Return On Equity of -178.73%. This is in the lower half of the industry: ADIL underperforms 72.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -142.26% | ||
| ROE | -178.73% | ||
| ROIC | N/A |
ROA(3y)-197.33%
ROA(5y)-210.06%
ROE(3y)-279.33%
ROE(5y)-332.84%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- ADIL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- The number of shares outstanding for ADIL has been increased compared to 1 year ago.
- ADIL has more shares outstanding than it did 5 years ago.
- ADIL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- ADIL has an Altman-Z score of -22.66. This is a bad value and indicates that ADIL is not financially healthy and even has some risk of bankruptcy.
- ADIL's Altman-Z score of -22.66 is on the low side compared to the rest of the industry. ADIL is outperformed by 85.86% of its industry peers.
- ADIL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -22.66 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- A Current Ratio of 4.34 indicates that ADIL has no problem at all paying its short term obligations.
- The Current ratio of ADIL (4.34) is better than 62.30% of its industry peers.
- A Quick Ratio of 4.34 indicates that ADIL has no problem at all paying its short term obligations.
- ADIL has a better Quick ratio (4.34) than 64.40% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.34 | ||
| Quick Ratio | 4.34 |
3. Growth
3.1 Past
- ADIL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 67.69%, which is quite impressive.
EPS 1Y (TTM)67.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.95%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- ADIL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.93% yearly.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y73.71%
EPS Next 2Y34.07%
EPS Next 3Y21.89%
EPS Next 5Y12.93%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for ADIL. In the last year negative earnings were reported.
- Also next year ADIL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- ADIL's earnings are expected to grow with 21.89% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.07%
EPS Next 3Y21.89%
5. Dividend
5.1 Amount
- ADIL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
ADIAL PHARMACEUTICALS INC / ADIL FAQ
What is the fundamental rating for ADIL stock?
ChartMill assigns a fundamental rating of 2 / 10 to ADIL.
Can you provide the valuation status for ADIAL PHARMACEUTICALS INC?
ChartMill assigns a valuation rating of 1 / 10 to ADIAL PHARMACEUTICALS INC (ADIL). This can be considered as Overvalued.
How profitable is ADIAL PHARMACEUTICALS INC (ADIL) stock?
ADIAL PHARMACEUTICALS INC (ADIL) has a profitability rating of 0 / 10.
What is the financial health of ADIAL PHARMACEUTICALS INC (ADIL) stock?
The financial health rating of ADIAL PHARMACEUTICALS INC (ADIL) is 6 / 10.
What is the expected EPS growth for ADIAL PHARMACEUTICALS INC (ADIL) stock?
The Earnings per Share (EPS) of ADIAL PHARMACEUTICALS INC (ADIL) is expected to grow by 73.71% in the next year.